Breaking News Bar
posted: 7/18/2012 10:02 AM

Abbott profit tops estimates as sales of Humira increase

hello
Success - Article sent! close
 
Bloomberg News

Abbott Laboratories, in the process of splitting into two companies, reported second-quarter earnings that beat analysts' estimates as sales increased for the company's top-selling drug, arthritis medicine Humira.

Earnings excluding one-time items of $1.23 a share beat by 1 cent the average of 19 analyst estimates compiled by Bloomberg. Revenue rose 2 percent to $9.8 billion, helped by $2.3 billion in Humira sales, the Libertyville Township-based company said in a statement today.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Abbott said that the breakup into one company focused on new drugs and the other on medical devices, generic medicines and nutritional drinks is still set for the end of the year. Bond investors are looking for Abbott to provide details on what will happen with its credit ratings at that point, said Joel Levington, managing director of corporate credit at Brookfield Investment in New York.

"A solid performance for Abbott," Levington said in an e- mail today. "However, for bondholders the cloud over the credit profile remains."

Abbott rose less than 1 percent to $66.51 at 9:38 a.m. New York time. The shares had gained 25 percent in the last 12 months through yesterday.

Net income declined 11 percent to $1.73 billion, or $1.08 a share, from $1.94 billion, or $1.23, Abbott said. Costs relating to the split-up reduced results by 4 cents a share, while expenses from asset acquisitions cut 5 cents a share.

Excluding the foreign currency impact, global sales would have risen 6.7 percent, the company said. Abbott reiterated its forecast of full-year earnings, excluding one-time items, of $5 to $5.10 a share.

The pharmaceutical side of Abbott has experimental therapies for the treatment of hepatitis C, and is in a race with drugmakers including Bristol-Myers Squibb Co. and Gilead Sciences Inc. to develop new methods of treatment for the virus.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.
    help here